Forrest Blocker

NeoGenomics (United States) — United States

Medicine · Health Sciences

6h-index317citations27works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(11), Cancer Genomics and Diagnostics(9), Myeloproliferative Neoplasms: Diagnosis and Treatment(4), RNA and protein synthesis mechanisms(3), Cancer Immunotherapy and Biomarkers(2)

Publications27 total

Abstract 2934: Pattern of PIK3CA co-alterations in endometrial cancer
Cancer Research·2022
Abstract 2281: Molecular profiling of the RUNX1 RUNT domain in myeloid disorders
Cancer Research·2022
Abstract 2238: A novel comprehensive breakpoint-targeted assay for clinically actionable RNA fusions and aberrant RNAs in solid tumors
Cancer Research·2021
TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity.
Journal of Clinical Oncology·2021· 2 cited
Abstract 182: A comprehensive genomic profiling approach to interrogate hematologic malignancies using a novel multimodal next generation sequencing assay in a single-tube
Cancer Research·2020
Abstract 3170: Different genomic mutations signatures are associated to specific PD-L1/TMB states on lung cancer with potential value for patients screening for immunotherapy
Cancer Research·2020
STAG2-mutated AML patients: ASXL1 cohesin binding motif status and mutation landscape.
Journal of Clinical Oncology·2020· 1 cited
Role of epigenetic regulators in single-base substitution patterns in AML.
Journal of Clinical Oncology·2020
Comparison of diagnostic methodologies to detect chromosomal abnormalities.
Journal of Clinical Oncology·2019· 3 cited
Abstract 4524: Immunohistochemistry and alternative FISH testing in breast cancer with <i>HER2</i> equivocal amplification
Cancer Research·2018· 1 cited
Association between microsatellite instability and <i>BRAF</i>, <i>TP53</i>, <i>PTEN</i>, and <i>KRAS</i> mutations in colorectal cancer.
Journal of Clinical Oncology·2018
Identifying new biomarkers and targeted molecules for immunotherapy using targeted RNA next generation sequencing.
Journal of Clinical Oncology·2018
Mismatch repair deficiency testing for immune checkpoint therapy: Immunohistochemistry vs microsatellite instability.
Journal of Clinical Oncology·2018
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Breast Cancer Research and Treatment·2018· 40 citedOpen Access
Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancer
Oncotarget·2018· 53 citedOpen Access
IDH1 and IDH2 : Founding or Progressor Mutations in Myeloid Neoplasms
Blood·2017· 2 cited
Using Targeted Enrichment RNA Sequencing in the Diagnosis of Hematologic Neoplasms in Fresh and Paraffin-Embedded Tissue
Blood·2017
Liquid Biopsy As a Diagnostic Test for Myelodysplastic Syndrome and Other Acute and Chronic Myeloid Neoplasms
Blood·2017
Clonal Hematopoiesis in Normal Individuals Is Not Random and Likely Reflects Early MDS
Blood·2017
FLT3 Mutation in Acute Myeloid Leukemia: Primary or Secondary Mutation?
Blood·2017
page 1 of 2Next →

Frequent Co-authors

Vincent Funari(20), Sally Agersborg(16), Maher Albitar(13), Wanlong Ma(10), Shiping Jiang(9), Lawrence M. Weiss(9), Sucha Sudarsanam(8), Ivan De Dios(8), Madhuri Paul(6), Wayne Chen(5), Frank Scarpa(5), Jennifer Hummel(4), Cynthie Wong(3), Rachel Daringer(3), Wendy Wolfson(3), Babak Shahbaba(3), Ryan Bender(3), Alan M. Lambowitz(2), Christopher Mixon(2), Thanh Thi Ngoc Nguyen(2)